RelabotulinumtoxinA improves frown lines, crow’s feet simultaneously for up to 6 months

New phase 3 data showed that a single dose of relabotulinumtoxinA significantly improved glabellar and lateral canthal lines when treated alone or simultaneously with a duration of up to 6 months, Galderma announced in a press release.
These results are from the randomized, double-blind, placebo-controlled, phase 3 READY-3 trial, which assessed the safety and efficacy of relabotulinumtoxinA in patients with moderate to severe glabellar and lateral canthal lines, also known as frown lines and crow’s feet, respectively.
“These positive data from the phase 3 READY-3 trial show that

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart